Fabio Pammolli participated, as invited speaker, to the following events:
The Switch Project Team has posted new items:
Questa Nota è un insieme articolato di evidenze empiriche sull’evoluzione del mercato dei prodotti farmaceutici a brevetto scaduto (off patent) in Europa, con un focus sull’Italia. Lo studio esamina il mercato off patent nel suo complesso, prendendo in considerazione gli andamenti in prezzi e volumi di tutti i prodotti interessati dalla scadenza brevettuale. Dopo aver evidenziato le principali differenze tra Paesi in termini di composizione complessiva del mercato, lo studio si concentra sulla descrizione degli effetti della scadenza del brevetto su prezzi e volumi, a valore di prezzo ex factory. Le elaborazioni si riferiscono a una base di dati che copre oltre 300.000 prodotti commercializzati attraverso il canale di vendita retail in 15 Paesi Europei, estratti dal database MIDAS di IMS Health, per i 12 anni che vanno da aprile 2001 a marzo 2013.
I risultati principali del lavoro possono essere riassunti nei termini seguenti:
Citazione: Laura Magazzini, Fabio Pammolli, Valentina Tortolini
Karl Claxton and colleagues at the University of York have recently published a working paper on Methods for the Estimation of the NICE Cost Effectiveness Threshold. Since a guideline was issued in 2004, NICE has used standard values of £20-30,000 as cost-effectiveness threshold. These are effectively equivalent to the cost per quality adjusted life year gained by investing in a new technology at the expenses of an already existing intervention.
This paper tries to produce an updated version of the cost-effectiveness threshold, based on empirical evidence (eg programme budgeting data for the English NHS). The methodology used is quite complex – technically, the authors used an instrumental variables approach within a structural equation setting – and aims at simultaneously estimating the impact of the level of investment (and other variables) on health outcomes and the impact the overall budget constraint (and other variables) on the level of spending for a given health programme. Their main result is to suggest a slightly lower value to be used by NICE (£18,317).
While there are some major limitation (eg the availability of data for all the different programmes, to be used to translate the impact of expenditure into changes in quality of life), the paper is extremely interesting, because it may suggest a generalised framework which would allow different settings to compute their own cost-effectiveness threshold. Again, availability of suitable data may represent a major barrier to the wider applicability of the method.
The Office for Health Economics has also produce a critique of this paper, which is available here.
CERM will participate, with invited presentations, at the following upcoming events:
These studies, financed by the ICT for Health and Wellbeing unit of the European Commission (DG Connect), are at the basis of our work in the field of eHealth. Their topics range from the impact of eHealth solutions on society to analyses of each Member State and case studies.
Istituzioni forti per crescere
Citazione: Mauro Marè e Fabio Pammolli
Quello scatto d’orgoglio necessario a far ripartire il motore Italia
Citazione: Mauro Marè e Fabio Pammolli
Giuseppe Carone, Mauro Marè, Fabio Pammolli e Nicola Salerno discutono i due rapporti sulle finanze pubbliche della Commissione Europea: "The 2012 Ageing Report" e "Fiscal Sustainability Report 2012" (entrambi pubblicati nella collana European Economy). Il seminario a porte aperte si svolge presso l’Auditorium "Cappella Guinigi" di IMT – Alti Studi di Lucca.
